A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs VT EBV (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- Sponsors ViGenCell
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.
- 15 Feb 2019 Planned initiation date changed from 18 Feb 2019 to 18 Mar 2019.
- 21 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 18 Feb 2019.